BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms
Blood · 2024
DOI: 10.1182/blood.2023022499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Holly Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Divisions of Hematology and Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Neoplasms, Plasma Cell. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Bispecific antibodies that engage T cells to target B-cell maturation antigen or G-protein–coupled receptor class C group 5 member D have demonstrated remarkable efficacy in heavily pretreated relapsed or refractory multiple myeloma (MM), leading to the recent accelerated approval of teclistamab, elranatamab, and talquetamab by health agencies. Future challenges, however, remain to define their optimal dosing schedule and duration, sequencing, and integration with established anti-MM therapeutics as well as delineating the biological and clinical mediators of immune escape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Divisions of Hematology and Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Holly Lee, Paola Neri, Nizar J Bahlis
Zitieren
APA
Lee, H., Neri, P., & Bahlis, N. J. (2024). BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. https://doi.org/10.1182/blood.2023022499
Vancouver
Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024. doi:10.1182/blood.2023022499
BibTeX
@article{Lee2024,
author = {Lee, Holly and Neri, Paola and Bahlis, Nizar J},
title = {BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms},
journal = {Blood},
year = {2024},
doi = {10.1182/blood.2023022499}
}
EUVIMED